home · filing · 0001104659-26-076352
8-K filed June 22, 2026, 4:01 PM ET
ticker AVBP
CIK 0001868279
other
confidence high
sentiment neutral
materiality 0.10
ArriVent BioPharma announces 2026 annual meeting voting results; directors elected, auditor ratified
ArriVent BioPharma, Inc.
Stockholders elected James Healy, John Hohneker, and Stuart Lutzker as Class II directors for three-year terms.
Healy received 18,058,285 votes for; Hohneker 28,043,164; Lutzker 29,495,923; broker non-votes 3,832,858 each.
Ratification of PricewaterhouseCoopers LLP as auditor for FY 2026 passed with 33,411,773 votes for, 829 against.
Quorum of 33,418,793 shares (72.07% of eligible) was present at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ArriVent BioPharma, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.
Proposal director election
Outcome passed
Meeting 2026-06-18
Exact text from the filing
1. Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-votes James Healy, M.D., Ph.D. 18,058,285 11,527,650 3,832,858 John Hohneker, M.D. 28,043,164 1,542,771 3,832,858 Stuart Lutzker, M.D., Ph.D. 29,495,923 90,012 3,832,858
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ArriVent BioPharma, Inc. shareholders approved Auditor Ratification at the 2026-06-18 meeting.
Proposal auditor ratification
Outcome passed
Meeting 2026-06-18
Exact text from the filing
2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 33,411,773 829 6,191 0
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-26-076352
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.